MS News: September 2014

image multiple sclerosis header news

It has been a big and very busy September for researchers, clinical trials and pharmaceutical companies. Early this month, the Joint ACTRIMS/ECTRIMS Meeting took place in Boston. For more, please check the extensive website of the conference.

Research news

  1. Johns Hopkins Multiple Sclerosis Center receives MS research grant from Progressive Alliance – The Johns Hopkins Multiple Sclerosis Center is the recipient of one of 22 research grants offered to investigators in nine countries.
  2. $31.4 Million in Funding Earmarked For Progressive Multiple Sclerosis Research
    Multiple Sclerosis News Today – Progressive Multiple Sclerosis The first round of 22 research grants have been awarded to projects in nine countries by the International Progressive Alliance.
  3. New MR technique offers new insight into multiple sclerosis – A new MR technique called macromolecular proton fraction (MPF) mapping revealed that patients with multiple sclerosis (MS) lose myelin — fatty protective sheath around nerve fibers.
  4. Study links slowed processing speed with executive deficits in individuals with multiple sclerosis – “Does slowed processing speed account for executive deficits in multiple sclerosis?
  5. Cognitive Training Improves Thalamic Connectivity in MS
    Medscape – … A new study shows that cognitive training using a commercially available game led to clinical improvements in patients with multiple sclerosis (MS).
  6. Kessler Foundation multiple sclerosis researchers find role for working memory in cognitive reserve
    Science Codex – Kessler Foundation scientists have shown that working memory may be an underlying mechanism of cognitive reserve in multiple sclerosis
  7. Diabetes and multiple sclerosis can be reversed say scientists
    The Standard Digital News – Diabetes and multiple sclerosis can be reversed say scientists. Updated … could be a cure for conditions like Type 1 diabetes and multiple sclerosis.

Clinical trials

  1. Multiple Sclerosis new drug candidate has promise – Results from a six-month Phase 2 study of 258 patients suffering from multiple sclerosis show the drug candidate RPC1063 decreased the annualized relapse rate by 53%
  2. Multiple Sclerosis: Generic Copaxone Demonstrates Equivalent Safety and Efficacy
    Medical Research News and Interviews_ – Dr. Cohen: The primary objective of the GATE trial was to compare the efficacy and safety of generic glatiramer acetate.
  3. Teva, Active Biotech Present Positive Findings for RRMS Experimental Therapy Laquinimod
    Multiple Sclerosis News Today – RRMS from Teva During the 30th Congress of the European Committee for Research and Treatment in Multiple Sclerosis (ECTRIMS) last week in Boston presented new follow-up data.
  4. Biogen Idec’s Study Reviews Positive Results Over Five Years of Tecfidera RRMS Treatment
    Multiple Sclerosis News Today – to provide strong and sustained efficacy to patients with relapsing-remitting multiple sclerosis (RRMS), at last week’s ACTRIMS-ECTRIMS summit.
  5. Multiple Sclerosis Trial for Lisinopril Granted $1.4 Million in New Funding From NCATS
    Multiple Sclerosis News Today – The Repurposing a Generic ACE Inhibitor to treat Multiple Sclerosis funding was granted by the National Center for Advancing Translational Sciences.
  6. Novel MS Therapy from GeNeuro Performed Well in Phase 2a Clinical Trial
    Multiple Sclerosis News Today – GNbAC1 MS drug A novel therapeutic from GeNeuro to treat multiple sclerosis showed promising results in a one-year, open-label extension phase.
  7. Mylan’s Generic Copaxone Injection ANDA Approved for Filling by the FDA
    Multiple Sclerosis News Today – However, there are no controlled clinical trials that verified its effects on the reduction of the progression of the disability caused by multiple sclerosis.

Medical treatment news

  1. Nyack Hospital named MS comprehensive care center
    The Journal News | – The National Multiple Sclerosis Society has named Nyack Hospital as one of its centers of comprehensive care for people who have the disease.
  2. AbbVie, Biogen to file MS drug next year
    Medical Marketing and Media – Phase-III results of the AbbVie-Biogen Idec experimental multiple sclerosis shot Zinbryta (daclizumab) indicate the drug bests Biogen’s injectable
  3. Novartis Presents Data on Multiple Sclerosis Drug Gilenya – Analyst Blog
    NASDAQ – Novartis ( NVS ) presented encouraging data on multiple sclerosis (MS) drug, Gilenya, from a follow-up extension study, LONGTERMS.
  4. EMD Serono Presents New Data on Rebif ® (Interferon beta-1a) and Multiple Sclerosis Pipeline at …
    Canada NewsWire (press release) – Data include post-hoc assessments of controlled studies in relapsing MS regarding evolution of gadolinium-enhancing lesions.
  5. Stretch It Out: Yoga Eases Multiple Sclerosis Symptoms in Pilot Study
    Healthline – Stretch It Out: Yoga Eases Multiple Sclerosis Symptoms in Pilot Study. Researchers bent over backwards to help those with MS
  6. Real-World Analysis of AMPYRA Multiple Sclerosis Drug Presented by Acorda and HealthCore
    Multiple Sclerosis News Today – Acorda Therapeutics will present results of a study analyzing AMPYRA (dalfampridine) Extended Release Tablets in multiple sclerosis patients
  7. Remyelination Therapy Promising in Multiple Sclerosis
    Medscape – An experimental monoclonal antibody for multiple sclerosis (MS) that enhances remyelination has shown promise in phase 1 studies.

Business news

  1. Beta-Interferon, Glatiramer Acetate Cost-Effective in MS
    Medscape – The study was presented at MS Boston 2014, the 2014 Joint Americas and European Committees for Treatment and Research in Multiple Sclerosis
  2. Biogen: Still Leading The Multiple Sclerosis Market
    Bidness ETC – Multiple sclerosis (MS), despite being a relatively rare disease, has turned into a lucrative market for many pharmaceuticals,
  3. Market Report, “Global Multiple Sclerosis Drugs Market 2014-2018 “, published
    USPRwire (press release) – [USPRwire, Wed Sep 03 2014] Multiple sclerosis is a chronic, inflammatory medical condition that results in demyelination, axonal transection, etc.

© Willeke Van Eeckhoutte and Ireland, Multiple Sclerosis & Me, 2011-2014. Unauthorized use and/or duplication of this material without express and written permission from this blog’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Willeke Van Eeckhoutte and Ireland, Multiple Sclerosis & Me with appropriate and specific direction to the original content.

6 thoughts on “MS News: September 2014

Your thoughts?

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.